The BRACELET-1 study revealed that pelareorep exceeded one year of median overall survival compared to paclitaxel monotherapy, supporting the potential for a future registration-enabling study.

Oncolytics plans to enroll approximately 55,000 patients in the U.S. who require better treatment options for metastatic breast cancer, contingent on favorable outcomes from the forthcoming study.

A new cohort in the GOBLET study, funded by The Pancreatic Cancer Action Network, is evaluating pelareorep combined with modified FOLFIRINOX and atezolizumab, with initial patient dosing reported to begin in June 2024.

The expanded enrollment in anal cancer studies aims to evaluate pelareorep's efficacy in treating unresectable squamous cell carcinoma of the anal canal, with initial results expected in early 2025.

Oncolytics will showcase its clinical progress and partnership opportunities at the Biotech Showcase and engage with investors during the J.P. Morgan Healthcare Conference in January 2025.

Key upcoming milestones for Oncolytics include finalizing the master protocol for the PDAC study and presenting updated efficacy data from various cohorts at the ASCO GI Symposium in January 2025.

These milestones are expected to be pivotal for ongoing gastrointestinal cancer programs, as the company continues to advance its innovative therapies.

Oncolytics Biotech Inc. has made significant strides in 2024, particularly with promising results from the BRACELET-1 study, which demonstrated notable efficacy for pelareorep in treating HR+/HER2- metastatic breast cancer.

Following a productive meeting with the FDA, Oncolytics has established progression-free survival as the primary endpoint for an upcoming registration-enabling study focused on breast cancer.

In addition to breast cancer, the GOBLET study has shown promising results in treating pancreatic ductal adenocarcinoma (PDAC), with objective response rates more than double that of historical controls.

Oncolytics is collaborating with the Global Coalition for Adaptive Research (GCAR) on a registration-enabling study for pelareorep in metastatic pancreatic cancer, building on the favorable data from the GOBLET study.

Enrollment has also expanded in the GOBLET study for anal cancer, where preliminary data suggests a tripling of response rates compared to historical controls, paving the way for a potential registration-enabling study.